Phio Pharmaceuticals to Highlight Self-delivering RNAi Technology at SITC 2019

On October 29, 2019 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that several posters featuring INTASYL will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2019 Annual Meeting, held November 6-10 at the Gaylord National Hotel and Convention Center in National Harbor, MD (Press release, Phio Pharmaceuticals, OCT 29, 2019, View Source [SID1234549982]). Three posters, reflecting internal work and work in collaboration with Iovance Biotherapeutics, Inc. and the Karolinska Institutet, will be highlighting Phio’s proprietary INTASYL technology for "weaponizing" T cells against cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Poster: P149
Date: Friday November 8, 2019
Title: Silencing PD-1 using self-delivering RNAi PH-762 to improve Iovance TIL effector function using Gen 2 manufacturing method
Category: Cellular Therapies
Authors: Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D’Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier

Poster: P222
Date: Saturday November 9, 2019
Title: Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer
Category: Cellular Therapies
Authors: Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD

Poster: P760
Date: Saturday November 9, 2019
Title: Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic
Category: Novel Single-Agent Immunotherapies
Authors: John A. Barrett, PhD; James Cardia; Melissa Maxwell; Mani D. Kadiyala, M.S.; Dingxue Yan, PhD; Winnie Tam; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD